DiaMedica Therapeutics (DMAC) Net Income towards Common Stockholders: 2017-2024
Historic Net Income towards Common Stockholders for DiaMedica Therapeutics (DMAC) over the last 8 years, with Dec 2024 value amounting to -$24.4 million.
- DiaMedica Therapeutics' Net Income towards Common Stockholders fell 26.40% to -$2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$10.6 million, marking a year-over-year decrease of 85.72%. This contributed to the annual value of -$24.4 million for FY2024, which is 26.12% down from last year.
- According to the latest figures from FY2024, DiaMedica Therapeutics' Net Income towards Common Stockholders is -$24.4 million, which was down 26.12% from -$19.4 million recorded in FY2023.
- In the past 5 years, DiaMedica Therapeutics' Net Income towards Common Stockholders ranged from a high of -$12.3 million in FY2020 and a low of -$24.4 million during FY2024.
- Over the past 3 years, DiaMedica Therapeutics' median Net Income towards Common Stockholders value was -$19.4 million (recorded in 2023), while the average stood at -$19.2 million.
- Data for DiaMedica Therapeutics' Net Income towards Common Stockholders shows a maximum YoY plummeted of 41.72% (in 2023) over the last 5 years.
- DiaMedica Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$12.3 million in 2020, then dropped by 10.58% to -$13.6 million in 2021, then decreased by 0.62% to -$13.7 million in 2022, then plummeted by 41.72% to -$19.4 million in 2023, then decreased by 26.12% to -$24.4 million in 2024.